Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cyclin dependent kinase inhibitors - Quest PharmaTech

Next Previous
Drug Profile

Research programme: cyclin dependent kinase inhibitors - Quest PharmaTech

Alternative Names: 2127 (CDK immunomodulator) - Quest PharmaTech; ACP-2127

Latest Information Update: 03 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Quest PharmaTech
  • Class Antineoplastics; Macrolides
  • Mechanism of Action Cyclin-dependent kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Nov 2018 OncoCare Therapeutics in-licenses Targeted Cancer Therapy Technology from Quest PharmaTech for USA
  • 16 Mar 2018 Preclinical trials in Cancer in Canada (unspecified route) (Quest PharmaTech pipeline, March 2018)
  • 30 Jul 2013 Discontinued - Preclinical for Cancer in Canada (unspecified route) before 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top